IP Library Granted Patent US 11,795,491
Granted Patent B2
US 11,795,491 · App. 15/819,345 · Granted Oct 24, 2023

Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same

Inventors: Tayyaba Hasan (Arlington, MA); Ulysses W. Sallum (Quincy, MA); Sarika Verma (Waltham, MA); Gerard Nau (Sharon, MA)
Assignee: The General Hospital Corporation
C12Q1/34C07D501/52C12Q1/04G01N33/542G01N33/56911G01N2333/986
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,795,491
App. No.
15/819,345
Granted
Oct 24, 2023
Kind
B2
Abstract

The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases.

Claims (14)

1. A method of measuring susceptibility of bacteria in a sample to a beta-lactam antibiotic, wherein the method comprises:

(a) contacting the sample with:

(i) a composition comprising a compound according to formula I: X-L-X′,

wherein L is a cephalosporin linker or fragment thereof, and both X and X′ are bodipy dyes, wherein the bodipy dyes are quenched by a static quenching mechanism when L is uncleaved, to form a standard; and

(ii) a composition comprising the beta-lactam antibiotic and the composition of (i), to form a test sample;

(b) light-activating the standard and the test sample to produce a fluorescence signal;

(c) quantifying the fluorescence signal with a detector to obtain a result;

(d) comparing the test sample result to the standard result; and

(e) if the amount of the measured fluorescence in the test sample is less than the amount of measured fluorescence in the standard, then the bacteria is determined to be susceptible to the β-lactam antibiotic.

2. The method of claim 1 , wherein the sample comprises whole blood, plasma, serum, nasal secretions, sputum, saliva, urine, sweat, transdermal exudates or cerebrospinal fluid.

3. The method of claim 1 , wherein the sample is a biological sample isolated from an infection in a subject.

4. The method of claim 3 , wherein the infection is caused by an antibiotic-resistant pathogen.

5. The method of claim 1 , wherein the bodipy dye is selected from the group consisting of: 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, succinimidyl ester; 6-dibromo-4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-3,5-dipropionic acid; 4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic acid; 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic acid succinimidyl ester; 4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid; 4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid sulfosuccinimidyl ester or sodium salt; 6-((4,4-difluoro-5,7-dimethyl-4-bora-3a,4a diaza-s-indacene-3-propionyl) amino) hexanoic acid; 6-((4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl)amino) hexanoic acid or succinimidyl ester; N-(4,4-difluoro-5, 7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl) cysteic acid, succinimidyl ester or triethylammonium salt; 6-4,4-difluoro-1,3-dimethyl-5-(4-methoxyphenyl)-4-bora-3a,4a 4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid; 4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 4,4-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 6-((4,4-difluoro-5-phenyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl)amino) hexanoic acid or succinimidyl ester; 4,4-difluoro-5-(4-phenyl-1, 3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 6-(((4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-yl) styryloxy) acetyl) aminohexanoic acid or succinimidyl ester; 4,4-difluoro-5-styryl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid; 4,4-difluoro-5-styryl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene-8-propionic acid; 4,4-difluoro-1,3,5, 7-tetramethyl-4-bora-3a,4a diaza-s-indacene-8-propionic acid succinimidyl ester; 4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-propionic acid succinimidyl ester; 6-(((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza s-indacene-3-yl) phenoxy) acetyl) amino) hexanoic acid or succinimidyl ester; and 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy) acetyl) aminohexanoic acid or succinimidyl ester.

6. The method of claim 1 , wherein the bodipy dye is selected from the group consisting of: 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, succinimidyl ester.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2018
From: NAU, GERARD
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 044986/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2018
From: HASAN, TAYYABA; SALLUM, ULYSSES W.; VERMA, SARIKA
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 044986/0991 →
Continuity (3)
Continuation 12990997
Provisional Application 61050453 · May 5, 2008
Related Publication 20180094292A1 · Apr 5, 2018